What FDA approval without an ACIP vote means for Moderna’s first mRNA flu shot
mFLUSIVA is licensed for adults 50 and older as of 5 August, but the committee that usually turns a license into coverage has not met all year — and flu season is weeks away.
On 5 August the Food and Drug Administration licensed a flu shot. That is not the same act as putting it on a coverage schedule. Moderna announced FDA approval of mFLUSIVA (mRNA-1010) for seasonal influenza in adults 50 years of age and older — the first mRNA-based influenza vaccine, and the company’s fourth FDA-approved product. Moderna said it expects supply for the 2026–2027 U.S. respiratory season, in select retailers in the coming weeks, and that the file is under review in the European Union, Canada, and Australia. The Advisory Committee on Immunization Practices has not recommended it.
That gap is the story. FDA can authorize a vaccine. Affordable Care Act preventive-service coverage and CDC clinical policy still run through ACIP. The 2026–27 respiratory season is the clock. A licensed product with a split label — traditional approval in one age band, accelerated approval in the other — and no committee recommendation is a policy object, not a launch montage.
A split label on purpose
Read the indication before the platform narrative. Approval in ages 50 through 64 rests on a randomized, observer-blind, active-controlled Phase 3 trial, NCT06602024, which enrolled 40,805 adults aged 50 years and older across 11 countries. Primary objectives were safety and reactogenicity, and relative vaccine efficacy versus a standard-dose active comparator against RT-PCR-confirmed, protocol-defined influenza-like illness caused by any influenza A or B strain. Moderna’s 5 August release does not publish an rVE percentage. Neither should anyone else until the label or the trial paper is the source.
Use in adults 65 and older is accelerated approval, based on immunogenicity versus a high-dose inactivated influenza vaccine in NCT05827978, which enrolled 2,992 U.S. adults in that age group. The indication section is explicit: continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial.” Effectiveness in the older group is also supported, Moderna said, by a descriptive rVE analysis from the 40,805-person trial. Two age bands, two evidence standards, one brand name. Pharmacies will not explain that distinction at the counter. The label does.
MedCity News, covering the same 5 August approval, reported that the vaccine covers three flu strains and works by delivering mRNA that directs cells to produce full-length hemagglutinin. Moderna said approval followed unanimous recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee for adults 50 and older. Unanimous advice to FDA is not a recommendation from ACIP.
The committee that has not met
CDC’s own ACIP meetings page still lists three 2026 dates. March 18–19 and June 24–26 are marked cancelled “due to ongoing litigation.” October 21–23 remains on the calendar. No 2026 meeting appears under past meetings. The committee has not been abolished. It has not met, and MedCity reported that it has not discussed mFLUSIVA. A Federal Register notice of 27 March is more specific about the first cancellation: pursuant to a preliminary order issued on 16 March 2026 in American Academy of Pediatrics et al. v. Kennedy et al., No. 1:25-cv-11916 (D. Mass.), the March meeting “has been stayed until further notice.” MedCity reported that the Academy and other health organizations have sued HHS Secretary Robert F. Kennedy Jr. over the legality of his ACIP appointments. That lawsuit is process history, not a ban on mRNA influenza vaccines. The fact that matters for this season is simpler: no 2026 vote yet, an October date still on the calendar, and a flu season that will not wait for a quorum.
ACIP and CDC cannot revoke an FDA approval. They can leave a licensed product outside the recommendation that payers treat as policy. When CDC adopts an ACIP recommendation, MedCity notes, it becomes agency policy; how or whether a vaccine receives that recommendation affects payer coverage. The Affordable Care Act requires coverage of immunizations that receive an ACIP recommendation. Private insurance and Medicaid are not obligated, on the public record of 5 August, to cover mFLUSIVA this season. That is the open policy question.
How the file got here
MedCity reported that in February the agency sent a refuse-to-file letter, signed by Vinay Prasad, then director of the Center for Biologics Evaluation and Research, saying the clinical data were not from adequate and well-controlled studies. Prasad left the FDA in April. Moderna met with the agency; the FDA then agreed to review the vaccine, splitting the application by age group. That sequence is why 50–64 is a traditional approval and 65-and-older is accelerated. MedCity, citing the FDA approval letter, said the required work includes a post-marketing safety study evaluating deaths in a randomized population and an observational study for heart-safety risks and Guillain-Barré syndrome. Guillain-Barré is a rare, labeled risk of influenza vaccination in general. The Phase 3 program, Moderna said, showed an acceptable safety profile with no new safety concerns identified. The confirmatory trial is part of the 65-and-older license. So is the October calendar ACIP has not yet used.
A season without a vote
Moderna said it expects mFLUSIVA to be available for eligible populations in the United States for the 2026–2027 respiratory virus season. “Available” is a supply statement. It is not a coverage statement. William Blair analysts, in a note MedCity relayed, projected peak U.S. sales of $1.16 billion. That is a bank estimate, not a company forecast. More useful is what Moderna told the same bank: it does not expect mFLUSIVA to contribute meaningfully to revenue in the upcoming flu season, because of the time it takes to secure pharmacy contracts and vaccine recommendations.
The scientific claim for mRNA influenza has always been speed — strain selection closer to the season, a manufacturing clock measured in weeks rather than in eggs. That claim is not on trial in October. The coverage claim is. A first mRNA flu shot can be licensed in August, stocked in September, and still sit outside the immunization schedule that makes a preventive service free at the point of care. FDA did its part on 5 August. ACIP has not met to do its part. That is what approval without a vote means: a product that exists, a recommendation that does not, and a few weeks in which payers, pharmacies, and clinicians will have to decide what a license is worth without the committee that usually translates it into a claim.